CYIG signed a strategic cooperation agreement with Xi’an Putian Pharmacy
SHANDONG, China, August 8, 2014 (GLOBE NEWSWIRE) In order to expand their market and increase sales, China YCT International Group, Inc (CYIG) signed a strategic cooperation agreement with Xi’an Putian Pharmacy LLP on 8th August 2014. Therefore, Putian Pharmacy, as the sales agency, will be allowed to sell Huoliyuan capsules in 15 Chinese provinces, which indicates that the sales network of Huoliyuan capsules has captured all provincial markets in China by expanding market share as well as increasing unit sales.
CYIG is a biotechnology company, mainly focused on producing medicines and selling organic healthcare products. It is also dedicated to laying a solid foundation for building a nationwide sales and marketing network. Additionally, CYIG will be offering more incentives to strategic partners to encourage them to create more value for CYIG.
Mr. Xuzhong Ding, the director of marketing and sales for CYIG, said “Reaching the agreement with Putian Pharmacy accelerates the market development in South-West China, which then pushes CYIG into the entire Chinese market and lays a solid foundation for meeting a pre-determined sales target. Finally, I hope that our cooperation will lead to a better future. ”
Safe Harbor Statement
Certain statements in this press release, constitute forward-looking statements for
purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements regarding the Company's future performance. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the periodic reports that are filed with the
Securities and Exchange Commission. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.
For more information, please contact: